Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Consolidated Net Income (2017 - 2019)

Historic Consolidated Net Income for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' Consolidated Net Income fell 3222.7% to -$1.2 million in Q4 2019 from the same period last year, while for Sep 2020 it was -$1.2 million, marking a year-over-year increase of 6956.95%. This contributed to the annual value of -$4.3 million for FY2019, which is 3104.1% down from last year.
  • As of Q4 2019, Monopar Therapeutics' Consolidated Net Income stood at -$1.2 million, which was down 3222.7% from -$759448.0 recorded in Q3 2019.
  • Over the past 5 years, Monopar Therapeutics' Consolidated Net Income peaked at -$373839.0 during Q1 2017, and registered a low of -$14.9 million during Q3 2017.
  • Over the past 3 years, Monopar Therapeutics' median Consolidated Net Income value was -$828354.0 (recorded in 2018), while the average stood at -$2.0 million.
  • The largest annual percentage gain for Monopar Therapeutics' Consolidated Net Income in the last 5 years was 9551.92% (2018), contrasted with its biggest fall of 14001.24% (2018).
  • Monopar Therapeutics' Consolidated Net Income (Quarter) stood at -$736800.0 in 2017, then fell by 25.73% to -$926358.0 in 2018, then tumbled by 32.23% to -$1.2 million in 2019.
  • Its Consolidated Net Income was -$1.2 million in Q4 2019, compared to -$759448.0 in Q3 2019 and -$932109.0 in Q2 2019.